EGF and lung adenocarcinoma: Our experiments demonstrated that both EGFR and MEK1/2 inhibitors decrease EGF‐ and IFNγ‐induced PD‐L1 expression, potentially increasing immunogenicity of lung adenocarcinoma cells.